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Abstract: 
Given the tissue-specific nature of epigenetic processes, the assessment of disease-relevant 
tissue is an important consideration for epigenome-wide association studies (EWAS). Little is 
known about whether easily accessible tissues such as whole blood can be used to address 
questions about inter-individual epigenomic variation in inaccessible tissues such as the 
brain. We quantified DNA methylation in matched DNA samples isolated from whole blood 
and four brain regions (prefrontal cortex, entorhinal cortex, superior temporal gyrus and 
cerebellum) from 122 individuals. We explored covariation between tissues and the extent to 
which methylomic variation in blood is predictive of inter-individual variation identified in 
the brain. For the majority of DNA methylation sites, inter-individual variation in whole 
blood is not a strong predictor of inter-individual variation in the brain, although the 
relationship with cortical regions is stronger than with the cerebellum. Variation at a subset of 
probes is strongly correlated across tissues, even in instances when the actual level of DNA 
methylation is significantly different between them. A substantial proportion of this 
covariation, however, is likely to result from genetic influences. Our data suggest that for the 
majority of the genome, a blood-based EWAS for disorders where brain is presumed to be the 
primary tissue of interest will give limited information relating to underlying pathological 
processes. These results do not, however, discount the utility of using a blood-based EWAS 
to identify biomarkers of disease phenotypyes manifest in the brain. We have generated a 
searchable database for the interpretation of data from blood-based EWAS analyses 
(http://epigenetics.iop.kcl.ac.uk/bloodbrain).  
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Introduction: 
 
There is increasing interest in the role of epigenetic processes in health and disease, with the 
primary focus of most epigenetic epidemiological studies to date being DNA methylation. 
1
 
Platforms such as the Illumina 450K Human Methylation microarray (450K array) have 
enabled the economical, high-throughput profiling of methylomic variation across large 
numbers of samples and epigenome-wide association studies (EWAS), which aim to identify 
DNA methylation differences associated with environmental exposure and disease, are now 
underway for many types of pathology including cancer, 
2-4
 autoimmune disorders, 
5, 6
 
psychiatric phenotypes, 
7
 neurodevelopmental disorders 
8, 9
 and dementia. 
10, 11
 Despite the 
recent successes in identifying disease-associated epigenetic variation, the design, analysis 
and interpretation of EWAS requires careful attention; there are a number of critical issues 
that need to be considered in epigenetic epidemiology that preclude a simple re-analysis of 
DNA samples collected for genome-wide association studies (GWAS). 
9, 12-14
  
 
Of particular importance is the fact that, unlike germline genetic variation, epigenetic 
signatures are tissue-specific; therefore the selection of tissue type for epigenetic 
epidemiology is potentially critical. The ENCODE and the NIH Epigenomics Roadmap 
projects, 
15-17
 for example, have recently characterized the distinct epigenetic profiles 
defining human cell-types, highlighting how these reflect the developmental relationships 
between them. It is clear that intra-individual epigenetic differences (i.e. between tissues 
within a single person) greatly outweigh inter-individual differences within a specific tissue-
type. 
18-23
 Although many clinical and epidemiological studies are examining epigenetic 
variation in easily accessible cells obtained from tissues such as whole blood, the extent to 
which these can be used to address questions about inter-individual epigenomic variation in 
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inaccessible tissues such as the brain has not yet been systematically explored. Addressing 
this issue will be critical given the paucity of high-quality brain tissue from clinically well-
phenotyped patients and controls, especially if EWAS analyses require sample sizes 
approaching those necessary to identify genetic associations with complex disease 
phenotypes. Because the brain and blood originate from different developmental cell lineages 
and are epigenetically distinct, 
23
 it is clearly inappropriate to use blood as a proxy measure 
for actual brain DNA methylation profiles. Despite this, epidemiological studies using 
accessible peripheral tissues may still be informative in an epidemiological context if inter-
individual variation is correlated across tissues.  
 
In this study we quantified DNA methylation using the 450K array in a unique collection of 
matched DNA samples isolated from pre-mortem whole blood and four post-mortem brain 
regions (prefrontal cortex (PFC), entorhinal cortex (EC), superior temporal gyrus (STG) and 
cerebellum (CER)) dissected at autopsy from 122 individuals. We describe patterns of 
covariation across tissues and identify sites where estimates of DNA methylation in whole 
blood are predictive of inter-individual variation in DNA methylation across the four brain 
regions. Our data are available in an online searchable database 
(http://epigenetics.iop.kcl.ac.uk/bloodbrain) to enable the research community to explore the 
relationship between whole blood and brain DNA methylation patterns at specific locations 
across the genome. 
 
Results and Discussion: 
Cortex, cerebellum and blood are defined by very distinct profiles of DNA methylation 
We used the Illumina 450K array to quantify DNA methylation in four dissected brain 
regions (PFC: n = 114, EC: n = 108, STG: n = 117 and CER: n = 112) and matched pre-
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mortem whole blood samples (n = 80) from an overlapping set of 122 individuals 
(Supplementary Table 1). Following pre-processing, normalization and stringent quality 
control (see Materials and Methods), principal component (PC) analysis was performed 
across the full dataset (comprising 531 individual DNA samples and data for a pruned set of 
427,018 high-quality probes). The first PC, explaining 51.4% of the variance, clearly 
distinguishes between whole blood, cerebellum, and the three cortical regions 
(Supplementary Figure 1). A similar separation of these tissues is observed with the second 
PC which explains 29.4% of the variance. This observation concurs with previous studies 
comparing whole blood and brain samples based on smaller samples and using alternative 
technologies for assessing DNA methylation. 
23-25
 These differences between tissues are 
reflected in gene expression data, 
26, 27
 which confirms the cerebellum as being clearly 
distinguishable from cortical brain regions. The three cortical regions have strikingly similar 
DNA methylation profiles; although examination of further PCs, none of which explain more 
than 5% of the variance, starts to tease apart these regions, none of the top 20 PCs does this 
definitively (Supplementary Figure 1).  
 
Inter-individual variation and sex make a much smaller contribution to overall variation in 
autosomal DNA methylation than tissue differences 
We used linear regression models to calculate the proportion of variance in DNA methylation 
explained by tissue, individual and sex. Across autosomal probes, tissue is the strongest 
predictor of DNA methylation (Supplementary Figure 2), although there is a subset of 
probes for which individual predicts more of the variance (5.39% of all probes) than tissue 
type (see Supplementary Table 2).  Across all autosomal probes passing stringent QC (n = 
416,872), tissue explains > 50% of the variance in DNA methylation at 193,333 (46.4%) 
sites, compared to individual differences which explain > 50% of the variance at 4,669 
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(1.12%) sites (Figure 1A). These percentages increase to 66.2% and 1.61% respectively 
when limited to probes classified as being “blood variable” (n = 185,060) (see Materials and 
Methods). As expected, sex makes a strong contribution to variation observed at probes on 
chromosomes X and Y (n = 10,146), explaining >50% of the variance at 5,920 (58.3%) of 
these positions compared to tissue which explains >50% of the variance at only 1,359 
(1.34%) sites. In contrast, sex makes a very small contribution to autosomal variation, 
explaining >50% of the variance at only 18 (4.32x10
-3
%) of autosomal probes 
(Supplementary Figure 3). 
 
Inter-individual variation is correlated across tissues at a small number of sites 
Although patterns of DNA methylation are clearly distinct across different brain regions and 
blood, driven by highly significant mean differences in DNA methylation at multiple sites 
across the genome, 
23
 we were interested in exploring the extent to which inter-individual 
variation detected in blood reflects inter-individual variation in the three cortical regions and 
cerebellum. Focusing on autosomal DNA methylation sites characterized as being variable in 
whole blood (n = 185,060, see Materials and Methods), correlation coefficients across all 
individuals were calculated between DNA methylation in whole blood and each of the four 
brain regions. Randomly selecting pairs of ‘matched’ samples to derive the null distribution, 
we found a modest but highly-significant positive shift in the distribution of correlations for 
each of the four brain regions (PFC: Wilcoxon test P < 2.2x10
-308
, EC: P < 2.2x10
-308
, STG: P 
< 2.2x10
-308
, CER: P < 2.2x10
-308
), with a small peak highlighting a number of probes 
characterized by a near perfect correlation (Figure 1B-E). For the majority of probes, 
however, inter-individual variation in DNA methylation in whole blood explains only a small 
amount of the variation seen in any of the brain regions (Figure 2). For example, DNA 
methylation in whole blood is strongly correlated with levels in cerebellum (i.e. explaining 
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>50% of the variance) for only 1.19% of “blood variable” probes, and moderately correlated 
(i.e. explaining >20% of the variance) with 3.68% of “blood variable” probes. Of note, the 
extent of inter-individual correlation is significantly higher (P < 1.0
-308
) between whole blood 
and each of the three cortical regions than with the cerebellum, although the proportion of 
correlated probes is still low (Supplementary Table 3).  These data concur with previous 
small studies correlating inter-individual variation in DNA methylation between tissues. 
Slieker et al. compared DNA methylation profiles between blood and several internal organs 
and reported a comparable number of sites (5,532, 3,909, 10,905, and 2,446 sites for liver, 
subcutaneous fat, omentum and skeletal muscle respectively) with a strong relationship (r > 
0.8) with variation in blood. 
19
 Similarly, a study comparing DNA methylation in matched 
blood and buccal samples found only ~3% of 998 sites were characterized by an absolute 
Pearson correlation > 0.5. 
20
 Density plots of DNA methylation across the probes with the 
strongest positive correlations (> 0.95) between blood and brain indicate that many are 
characterized by a clear trimodal distribution of DNA methylation (Supplementary Figure 
4), suggesting that DNA sequence variation likely mediates much of the observed cross-
tissue similarities via processes such as allele-specific DNA methylation. 
28
 Many DNA 
methylation quantitative trait loci (mQTL) have consistent effects across tissues 
29, 30
; 
Supplementary Figure 5 shows a couple of examples where the correlated DNA 
methylation profiles across tissues is likely to result from mQTLs, as the distribution of DNA 
methylation levels cluster into distinct groups reflecting genotype, with consistent effects 
across tissues. 
 
 
For some loci, the extent to which inter-individual variation is correlated between whole 
blood and brain differs by brain region  
 8 
The extent to which inter-individual variation in whole blood is correlated with that in the 
brain is similar across the four brain regions (Supplementary Figure 6), with a highly 
significant correlation of probe-wise correlations. Of note, the three cortical regions are more 
similar to each other in this regard than the cerebellum, indicating that there is a subset of 
probes where variation in whole blood predicts variation in the cortex and not the cerebellum, 
and vice versa (for example see Supplementary Figure 7). This suggests that the extent of 
covariation between pairs of tissues can differ depending upon the tissues in question, and 
establishing a correlation between any two tissues does not imply a correlation between all 
tissues. Of additional interest are sites where there is a significant, but negative, correlation 
between blood and brain (see Supplementary Figure 8 for specific examples), a 
phenomenon that has been reported previously for certain loci. 
25
 This phenomenon is 
relatively rare, and most notable between DNA methylation in whole blood and cerebellum 
(Supplementary Table 4). 
 
Sites at which inter-individual variation in DNA methylation is highly correlated between 
whole blood and brain are enriched in CpG-rich promoter regions 
Sites at which DNA methylation is strongly correlated between whole blood and brain (r
2
 > 
0.5) are not equally distributed across the genome. Of note, we find a significant over-
representation at loci in the vicinity of transcription start sites (PFC: P = 1.34x10
-22
, EC: P = 
5.15x10
-21
, STG: P = 1.06x10
-18
, CER:
 
P = 1.34x10
-22
 ), 1
st
 exon (PFC: P = 2.48 x 10
-175
, EC: 
P = 8.78x10
-174
, STG: P = 6.72x10
-171
, CER: P = 3.50x10
-172
) and 5’UTR (PFC: P = 2.07 x 
10
-119
, EC: P = 5.04 x10
-120
, STG: P = 2.98x10
-119
, CER: P = 2.28x10
-118
) and a depletion in 
the gene body (PFC: P = 6.15x10
-94
, EC: P = 4.43x10
-97
, STG: P = 2.56x10
-87
, CER: P = 
1.85x10
-88
), 3’UTR (PFC: P = 2.92x10-24, EC: P = 1.06 x 10-23, STG: P = 2.02 x 10-21, CER: 
P = 4.74x10
-23
) and intergenic regions (PFC: P = 1.10x10
-72
, EC: P = 2.24 x 10
-65
, STG: P = 
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3.51 x 10
-71
, CER: P = 1.57 x 10
-86
) (Figure 4 and Supplementary Table 5). In addition 
there is enrichment in CpG islands (PFC: P < 2.2x10
-308
, EC: P < 2.2x10
-308
, STG:
 
P < 
2.2x10
-308
, CER: P < 2.2x10
-308
) and depletion in open sea (PFC: P = 8.16x10
-262
, EC: P = 
3.57 x 10
-276
, STG: P = 2.87x10
-273
, CER: P = 7.10x10
-244
) (Figure 4 and Supplementary 
Table 5).  
 
Covariation between tissues often occurs when absolute levels of DNA methylation are 
different 
It is a common misconception that a similar average level of DNA methylation between two 
tissues at a given locus is sufficient to establish that one of these tissues may be used as a 
proxy for the other. 
31
 In fact, for epidemiological studies that use peripheral tissues as a 
proxy, it is actually more important that the two tissues covary, regardless of their absolute 
DNA methylation levels. To demonstrate this point, Supplementary Table 6 lists 887 sites 
characterized by similar levels of DNA methylation between tissues (paired t-test P > 0.1) but 
no evidence for inter-individual covariation (r
2
 < 0.05), with specific examples shown in 
Supplementary Figure 9. In contrast, Supplementary Table 7 and Supplementary Figure 
10 demonstrate sites that are characterized by highly tissue-specific levels of DNA 
methylation (paired t-test P < 0.00001) but strong evidence for inter-individual covariation (r
2
 
> 0.5).  
 
Whole blood cannot be used as a proxy for DNA methylation sites that are only variable in 
the brain 
One potential caveat to performing an EWAS of a neurological/psychiatric phenotype using a 
peripheral tissue as a proxy is that a proportion of sites are characterized by limited inter-
individual variation in whole blood but high levels of inter-individual variation in the brain, 
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and vice versa. We defined probes as having ‘low’ variation when the range of DNA 
methylation values across the total sample < 5% and ‘high’ variation when the range of DNA 
methylation in the middle 80
th
 percentile of samples > 5%. Figure 5A shows that there are 
2,505 sites characterized by high inter-individual variation in whole blood but not in the 
cortex (STG) (see Supplementary Figure 11 and Supplementary Table 8 for 
corresponding data for the other cortical regions) and 6,909 sites that vary in whole blood but 
not in the cerebellum. Whether these sites are omitted from analyses (for example to reduce 
multiple testing burden) depends upon the ultimate aim of the study being undertaken; while 
they may not be able to inform directly about mechanistic processes in disease they could still 
represent useful biomarkers. In contrast, some sites are non-variable in whole blood but vary 
in the brain (see Figure 5B). 
 
 
Conclusion: 
Our data suggest that across the majority of the genome, an EWAS using whole blood for 
disorders where brain is the presumed to be the primary tissue of interest will give limited 
information relating to underlying pathological processes. However, there are a proportion of 
sites where inter-individual variation is correlated between whole blood and brain, and these 
results do not discount the utility of using a blood-based EWAS to identify potential 
biomarkers of psychiatric disease phenotypes. We have developed a searcheable online 
database (http://epigenetics.iop.kcl.ac.uk/bloodbrain/) to enable researchers to investigate 
the relationship between blood and brain for any probes on the Illumina 450K Beadchip array 
to aid in the interpretation of EWAS analyses of brain disorders.  
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Materials and Methods: 
Samples. 
We obtained entorhinal cortex (EC), prefrontal cortex (PFC), superior temporal gyrus (STG), 
and cerebellum (CER) tissue from 117 individuals archived in the MRC London 
Neurodegenerative Disease Brain Bank (http://www.kcl.ac.uk/iop/depts/cn/research/MRC-
London-Neurodegenerative-Diseases-Brain-Bank/MRC-London-Neurodegenerative-
Diseases-Brain-Bank.aspx). Ethical approval for the study was provided by the NHS South 
East London REC 3. All samples were dissected by trained specialists, snap-frozen and 
stored at −80 °C. Matched whole blood samples collected before death were available for 80 
samples (Supplementary Table 1) as part of the Alzheimer's Research UK funded study 
“Biomarkers of AD Neurodegeneration”, with informed consent according to the Declaration 
of Helsinki (1991).  Genomic DNA was isolated from ~100 mg of each dissected brain region 
or ~10ml whole blood stored in EDTA collection tubes using a standard phenol-chloroform 
extraction method, and tested for degradation and purity before analysis. 
 
Methylomic profiling  
500ng DNA from each sample was sodium bisulfite-treated using the Zymo EZ 96 DNA 
methylation kit (Zymo Research) according to the manufacturer's standard protocol. DNA 
methylation was quantified using the Illumina Infinium Human Methylation450K BeadChip 
(Illumina) using a Illumina HiScan System (Illumina). All samples were assigned a unique 
code for the purpose of the experiment and grouped by tissue and randomized with respect to 
other variables status to avoid batch effects, and processed in batches of four BeadChips. 
Illumina Genome Studio software was used to extract the raw signal intensities of each probe 
(without background correction or normalization). Raw data are downloadable from GEO 
with accession identifier GSE59685.  
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Data pre-processing 
All analyses were performed using R 3.0.2 
32
  and Bioconductor 2.13. 
33
 Signal intensities 
were imported into R using the methylumi package. 
34
 Initial quality control checks were 
performed using functions in the methylumi package to assess concordance between reported 
and gender inferred from the arrays. The 65 non-CpG SNP probes on the array were also 
used to confirm that all four brain regions and matched blood samples were sourced from the 
same individual. Data was subsequently pre-processed in the R package wateRmelon using 
the dasen function as previously described. 
35
 Prior to data analysis, we removed the 65 non-
CpG SNP probes, and probes characterized by either non-specific binding or containing 
common (minor allele frequency > 5%) SNPs within 10bp of the CG or single base extension 
position, identified from previously published lists. 
36, 37
   
 
Data analysis 
Separate linear regression models were used to calculate the proportion of variance explained 
(adjusted r squared) by a) brain region, b) individual, and c) sex for each DNA methylation 
site on the array across individuals for which data from all five tissues passed quality control. 
A subset of “blood variable” probes was identified by calculating the DNA methylation 
difference between the 10
th
 and 90
th
 percentile across all samples, and selecting sites where 
this was > 5% (all chromosomes n = 194,426; autosomes n = 185,060).  Sites characterized 
by overall differential DNA methylation between blood and each brain region were identified 
by a paired t-test of matched samples. Pairwise correlation coefficients were calculated 
between DNA methylation values from whole blood and each of the four brain regions across 
matched samples from linear regression models; the values were squared and multiplied by 
100 to obtain the percentage of variance explained for each probe. Samples were permuted 
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and correlations between DNA methylation in whole blood and brain were recalculated 
across unmatched pairs to establish the distribution in the scenario where there is no 
relationship between DNA methylation in blood and brain. The density curve of these 
simulated correlations was added to the histograms of the true correlation coefficients to 
represent the null distribution (Figure 1 and Supplementary Figure 4). The annotation file 
provided by Illumina for all probes on the array was used to classify DNA methylation sites 
into genomic feature and CpG island feature categories; any site with no UCSC gene 
annotation was classed as “intergenic”. Enrichment was calculated from a 2x2 Fisher’s Exact 
test, comparing the number of probes with blood-brain correlation r
2
 > 0.5 annotated to each 
feature category to the background of all probes.  
 
Web resources. 
A searchable database of matched blood and brain region DNA methylation data is available 
at http://epigenetics.iop.kcl.ac.uk/bloodbrain/. It reports the distribution of DNA 
methylation values in each tissue and the correlation of individual values between blood and 
each of the four brain regions for each probe on the 450K array. 
 
Acknowledgments 
We thank the National Institute for Health (NIHR) Biomedical Research Unit in Dementia in 
the South London and Maudsley NHS Foundation Trust (SLaM), Brains for Dementia 
Research (Alzheimer Brain Bank, UK), and the donors and families who made this research 
possible. Blood samples were collected as part of the Alzheimer's Research UK funded study 
“Biomarkers of AD Neurodegeneration”. This work was funded by US National Institutes of 
Health grant R01 AG036039 and UK Medical Research Council grant MR/K013807/1 to 
J.M.  
 14 
  
 15 
References 
1. Murphy TM, Mill J. Epigenetics in health and disease: heralding the EWAS era. 
Lancet 2014; 383:1952-4. 
2. Heyn H, Carmona FJ, Gomez A, Ferreira HJ, Bell JT, Sayols S, et al. DNA 
methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel 
epigenetic biomarker. Carcinogenesis 2013; 34:102-8. 
3. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human 
colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-
specific CpG island shores. Nat Genet 2009; 41:178-86. 
4. Lange CP, Campan M, Hinoue T, Schmitz RF, van der Meulen-de Jong AE, 
Slingerland H, et al. Genome-scale discovery of DNA-methylation biomarkers for blood-
based detection of colorectal cancer. PLoS One 2012; 7:e50266. 
5. Liu Y, Aryee MJ, Padyukov L, Fallin MD, Hesselberg E, Runarsson A, et al. 
Epigenome-wide association data implicate DNA methylation as an intermediary of genetic 
risk in rheumatoid arthritis. Nat Biotechnol 2013; 31:142-7. 
6. Rakyan VK, Beyan H, Down TA, Hawa MI, Maslau S, Aden D, et al. Identification 
of type 1 diabetes-associated DNA methylation variable positions that precede disease 
diagnosis. Plos Genet 2011; 7:e1002300. 
7. Pidsley R, Viana J, Hannon E, Spiers HH, Troakes C, Al-Saraj S, et al. Methylomic 
profiling of human brain tissue supports a neurodevelopmental origin for schizophrenia. 
Genome Biol 2014; 15:483. 
8. Ladd-Acosta C, Hansen K, Briem E, Fallin M, Kaufmann W, Feinberg A. Common 
DNA methylation alterations in multiple brain regions in autism. Molecular Psychiatry 2014; 
19:862-71. 
9. Berko ER, Suzuki M, Beren F, Lemetre C, Alaimo CM, Calder RB, et al. Mosaic 
epigenetic dysregulation of ectodermal cells in autism spectrum disorder. Plos Genet 2014; 
10:e1004402. 
10. De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L, et al. 
Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 
and other loci. Nat Neurosci 2014; 17:1156-63. 
11. Lunnon K, Smith R, Hannon E, De Jager PL, Srivastava G, Volta M, et al. 
Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat 
Neurosci 2014; 17:1164-70. 
12. Mill J, Heijmans BT. From promises to practical strategies in epigenetic 
epidemiology. Nat Rev Genet 2013; 14:585-94. 
13. Relton CL, Davey Smith G. Epigenetic epidemiology of common complex disease: 
prospects for prediction, prevention, and treatment. PLoS Med 2010; 7:e1000356. 
14. Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-wide association studies for 
common human diseases. Nat Rev Genet 2011; 12:529-41. 
15. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the 
human genome. Nature 2012; 489:57-74. 
16. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, et al. 
Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011; 
473:43-9. 
17. Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, Ernst J, Bilenky M, 
Yen A, et al. Integrative analysis of 111 reference human epigenomes. Nature 2015; 518:317-
30. 
 16 
18. Byun HM, Siegmund KD, Pan F, Weisenberger DJ, Kanel G, Laird PW, et al. 
Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue- and 
individual-specific DNA methylation patterns. Hum Mol Genet 2009; 18:4808-17. 
19. Slieker RC, Bos SD, Goeman JJ, Bovée JV, Talens RP, van der Breggen R, et al. 
Identification and systematic annotation of tissue-specific differentially methylated regions 
using the Illumina 450k array. Epigenetics Chromatin 2013; 6:26. 
20. Jiang R, Jones MJ, Chen E, Neumann SM, Fraser HB, Miller GE, et al. Discordance 
of DNA methylation variance between two accessible human tissues. Sci Rep 2015; 5:8257. 
21. Thompson TM, Sharfi D, Lee M, Yrigollen CM, Naumova OY, Grigorenko EL. 
Comparison of whole-genome DNA methylation patterns in whole blood, saliva, and 
lymphoblastoid cell lines. Behav Genet 2013; 43:168-76. 
22. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, Burger M, et al. DNA 
methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006; 38:1378-85. 
23. Davies MN, Volta M, Pidsley R, Lunnon K, Dixit A, Lovestone S, et al. Functional 
annotation of the human brain methylome identifies tissue-specific epigenetic variation 
across brain and blood. Genome Biol 2012; 13:R43. 
24. Farré P, Jones MJ, Meaney MJ, Emberly E, Turecki G, Kobor MS. Concordant and 
discordant DNA methylation signatures of aging in human blood and brain. Epigenetics 
Chromatin 2015; 8:19. 
25. Illingworth RS, Gruenewald-Schneider U, De Sousa D, Webb S, Merusi C, Kerr AR, 
et al. Inter-individual variability contrasts with regional homogeneity in the human brain 
DNA methylome. Nucleic Acids Res 2015; 43:732-44. 
26. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot 
analysis: multitissue gene regulation in humans. Science 2015; 348:648-60. 
27. Melé M, Ferreira PG, Reverter F, DeLuca DS, Monlong J, Sammeth M, et al. Human 
genomics. The human transcriptome across tissues and individuals. Science 2015; 348:660-5. 
28. Schalkwyk LC, Meaburn EL, Smith R, Dempster EL, Jeffries AR, Davies MN, et al. 
Allelic skewing of DNA methylation is widespread across the genome. Am J Hum Genet 
2010; 86:196-212. 
29. Gibbs JR, van der Brug MP, Hernandez DG, Traynor BJ, Nalls MA, Lai SL, et al. 
Abundant Quantitative Trait Loci Exist for DNA Methylation and Gene Expression in 
Human Brain. Plos Genet 2010; 6. 
30. Smith AK, Kilaru V, Kocak M, Almli LM, Mercer KB, Ressler KJ, et al. Methylation 
quantitative trait loci (meQTLs) are consistently detected across ancestry, developmental 
stage, and tissue type. Bmc Genomics 2014; 15:145. 
31. Smith AK, Kilaru V, Klengel T, Mercer KB, Bradley B, Conneely KN, et al. DNA 
extracted from saliva for methylation studies of psychiatric traits: evidence tissue specificity 
and relatedness to brain. Am J Med Genet B Neuropsychiatr Genet 2015; 168B:36-44. 
32. R Development Core Team. R: A Language and Environment for Statistical 
Computing.  . Vienna, Austria: R Foundation for Statistical Computing, 2008. 
33. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. 
Bioconductor: open software development for computational biology and bioinformatics. 
Genome Biol 2004; 5:R80. 
34. Davis S, Du P, Bilke S, Triche J, Bootwalla M. methylumi: Handle Illumina 
methylation data. R package version 2.14.0., 2015. 
35. Pidsley R, Y Wong CC, Volta M, Lunnon K, Mill J, Schalkwyk LC. A data-driven 
approach to preprocessing Illumina 450K methylation array data. Bmc Genomics 2013; 
14:293. 
 17 
36. Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, et al. 
Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium 
HumanMethylation450 microarray. Epigenetics 2013; 8:203-9. 
37. Price ME, Cotton AM, Lam LL, Farré P, Emberly E, Brown CJ, et al. Additional 
annotation enhances potential for biologically-relevant analysis of the Illumina Infinium 
HumanMethylation450 BeadChip array. Epigenetics Chromatin 2013; 6:4. 
 
 
  
 18 
Figure Legends 
Figure 1: Variation in DNA methylation in whole blood is correlated with variation in 
the brain for a small proportion of probes. A) the proportion of sites (y-axis) for which 
tissue (black), sex (red), or individual (green) explain a given percentage of DNA 
methylation variance (x-axis). B) to E) histograms showing the distribution of correlation 
coefficients between DNA methylation in whole blood and the four brain regions (PFC, EC, 
STG and CER). For all four brain regions the distribution of correlation coefficients is 
significantly skewed to the right, with stronger correlations seen between whole blood and 
cortical regions than between whole blood and cerebellum.  
Figure 2: Variation in DNA methylation in whole blood as a predictor of variation in 
the brain. Shown is the proportion of sites (y-axis) for which variation in blood explains a 
certain of percentage of DNA methylation variance (x-axis) in the PFC (black), EC (red), 
STG (green) and CER (blue) from the same individuals.  
Figure 3: DNA methylation in whole blood significantly covaries with that in the brain 
at some genomic loci. An example output of our online database 
(http://epigenetics.iop.kcl.ac.uk/bloodbrain) for blood-brain correlations at cg26039926. 
Shown is a boxplot of the distribution of DNA methylation values across all individuals split 
by tissue and four scatterplots demonstrating the relationship between DNA methylation in 
whole blood and four brain regions (PFC, EC, STG, CER). At this probe there is a highly 
significant correlation between individual variation in whole blood and that observed in all 
four brain regions. 
Figure 4: Sites at which inter-individual variation correlates between whole blood and 
brain are enriched in specific genic features. Bar charts plotting the percentage of sites 
annotated to particular genic feature categories and CpG Island annotations for the full set of 
“blood variable” sites, in addition to the subset of sites characterized by the highest 
correlation (r
2
 > 50%) between blood and brain. Fisher’s exact tests were used to test for 
either over or underrepresentation for each type of feature and are presented in 
Supplementary Table 2. 
Figure 5: EWAS analyses of brain phenotypes using whole blood DNA may potentially 
miss disease associated variation and interrogate DNA methylation sites that are not 
actually variable in the brain. Venn diagrams showing the overlap of DNA methylation 
sites that are A) variable in whole blood but not variable in the cortex (STG) or cerebellum 
and B) variable in the cortex (STG) and cerebellum but not in whole blood.   
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Supplementary Tables 
Supplementary Table 1: Summary of demographic information for all samples included in 
this study. 
Supplementary Table 2: Top 100 autosomal sites where individual predicts more of the 
variance in DNA methylation than tissue. Full table can be found at 
http://epigenetics.iop.kcl.ac.uk/bloodbrain/SupplementaryTables.xlsx 
Supplementary Table 3: Counts of sites where DNA methylation in blood is correlated with 
brain. 
Supplementary Table 4: Counts of sites where DNA methylation in blood is negatively 
correlated with brain. 
Supplementary Table 5: Results of tests for enrichment of blood-brain correlated DNA 
methylation sites in specific genomic or CpG island annotation categories. 
Supplementary Table 6: Table of 100 example sites characterized by similar levels of DNA 
methylation across blood and brain (paired t-test P > 0.1) but no evidence of inter-individual 
covariation (r
2
 < 0.05). The full table of 887 sites can be found at 
http://epigenetics.iop.kcl.ac.uk/bloodbrain/SupplementaryTables.xlsx 
Supplementary Table 7: Table of 100 example sites characterized by highly tissue-specific 
levels of DNA methylation (paired t-test P < 0.00001) but strong evidence for inter-
individual covariation (r
2
 > 0.5). The full table of 1,813 sitescan be found at 
http://epigenetics.iop.kcl.ac.uk/bloodbrain/SupplementaryTables.xlsx 
Supplementary Table 8: Table of 100 example sites which do not vary in whole blood but 
do vary in at least one brain region. The full table of 7,821 sites can be found at 
http://epigenetics.iop.kcl.ac.uk/bloodbrain/SupplementaryTables.xlsx 
 
 
 
